Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVanderbilt University Medical Center
About this trial
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.
Eligibility criteria
Qualifiers
Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
Able to give informed consent
Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
Disqualifiers
Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
Received chemotherapy during current hospitalization
Planning on major surgery within 10-15 days
Trial design
Treatments tested in this trial
- Libre 3 Plus Continuous Glucose Monitor
- Dexcom G7 Continuous Glucose Monitor
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1Vanderbilt University Medical Center37232, NashvilleTennessee, United States
Sponsors and collaborators
Vanderbilt University Medical Center
Lead sponsor
Source ClinicalTrials.gov